Study guide

3.2 Closed System Transfer Devices (CSTDs)

PTCB Hazardous Drug Management Certificate Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

0.1 Exam Facts, Format & Eligibility 0.2 Content Outline, Scoring & Registration 0.3 USP <800> Big Picture & How to Use This Guide

2 USP <800> Program Administration

1.1 USP <800> Scope, Purpose & Enforcement 1.2 The NIOSH Hazardous Drug List (2024 Update) 1.3 Assessment of Risk 1.4 Designated Person, SOPs & the Hierarchy of Controls

3 Training, Compliance & Recordkeeping

2.1 Training Requirements & Medical Surveillance 2.2 Hazard Communication, SDS & OSHA Requirements 2.3 Recordkeeping & Professional Guidelines

4 Primary Engineering Controls

3.1 Containment Primary Engineering Controls (C-PEC): BSCs & CACIs 3.2 Closed System Transfer Devices (CSTDs) 3.3 Nonsterile Controls and the C-SCA Distinction

5 Secondary Engineering Controls & Facility Design

4.1 Containment Secondary Engineering Controls (C-SEC): Negative Pressure & Air Exchange 4.2 Facility Layout: Storage, Unpacking & Sink Placement 4.3 Certification, ISO Classes & Emergency Equipment

6 Facility Cleaning Procedures

5.1 The Four-Step Cleaning Process 5.2 Wipe Sampling & Action Levels 5.3 Hazardous Waste Disposal & RCRA

7 Spill Response & Cleaning PPE

6.1 Spill Kits & Spill Response Procedures 6.2 PPE During Cleaning: Glove Change Frequency & Disposal

8 Dispensing & the Compounding Interface

7.1 USP <795>/<797> Interface for Hazardous Drugs 7.2 High-Risk Oral Hazardous Drugs 7.3 Tablet Splitting & Crushing Restrictions

9 Counting, Packaging & Patient Counseling

8.1 Counting, Packaging & Dedicated Equipment 8.2 Patient Counseling & Unit-Dose Labeling

10 PPE: Gloves, Gowns & Task-Based Selection

9.1 ASTM D6978 Chemotherapy Gloves & Double Gloving 9.2 Chemo Gowns & Gown Change Frequency 9.3 Task-Based PPE Selection

11 Respiratory Protection, Eye Protection & PPE Sequencing

10.1 Respiratory & Eye/Face Protection 10.2 Donning & Doffing Sequence

12 Transport & Receiving

11.1 Receiving Hazardous Drug Shipments 11.2 Internal Transport & Storage 11.3 Damaged/Leaking Shipments & Chain of Custody

13 Exam Readiness & Final Review

12.1 Domain-by-Domain Quick Review 12.2 Common Exam Traps & Final Checklist

3.2 Closed System Transfer Devices (CSTDs)

Key Takeaways Explain This Topic AI

A CSTD supplements containment and PPE; it does not replace a required C-PEC or an appropriate handling environment.

The administration requirement concerns NIOSH Table 1 antineoplastic HDs, a suitable dosage form and a physically and chemically compatible device.

USP <800> recommends CSTDs for compounding HDs but prohibits use of a device known to be incompatible with the specific HD.

Check exact product generations and instructions: the original US PhaSeal discontinuation notice excludes PhaSeal Optima.

Compatibility depends on the specific formulation, materials and intended pathway; do not generalise one formulation’s warning to every product containing the active ingredient.

Last updated: October 2026

What a closed-system drug-transfer device does

A closed-system drug-transfer device (CSTD) mechanically restricts environmental contaminants from entering the system and hazardous drug (HD) or vapour from escaping. It is a supplemental engineering control used along the drug-transfer pathway, rather than a substitute for a containment primary engineering control (C-PEC), an appropriate room or personal protective equipment (PPE).

The key exam distinction is the activity, drug classification, dosage form and compatibility described in the question. Knowing only that a drug is hazardous is insufficient to decide whether a particular CSTD requirement applies.

Read the administration requirement with its full scope

USP's January 2026 FAQ , questions 44–47, gives the following distinction:

Activity CSTD status under the chapter Conditions to retain

Administering a NIOSH Table 1 antineoplastic HD Required The dosage form allows CSTD use, and the device is physically and chemically compatible with that specific HD

Compounding HDs Recommended; not universally required by the chapter Do not use a device known to be physically or chemically incompatible with the specific HD

Other HD handling Do not infer a blanket requirement from the administration rule Apply the relevant task-specific controls, policies and applicable requirements

For USP <800>, the term antineoplastic refers to antineoplastic drugs included in NIOSH Table 1 . Table 1 also contains drugs that are not antineoplastics, so “Table 1” alone does not establish the full administration condition. Likewise, do not expand the specified rule into an assertion that every drug used to treat cancer, regardless of its classification, has identical containment requirements.

Imagine administration of a Table 1 antineoplastic by a route and dosage form for which a compatible CSTD is available. Treating the CSTD as merely optional would misstate the rule. Now consider preparation of that drug inside the required C-PEC: USP recommends a compatible CSTD for compounding, but the chapter's CSTD provision is not a universal compounding mandate. Applicable law or the facility's own requirements may be stricter; the recommendation does not authorise disregarding those obligations.

Keep the layers of protection distinct

The C-PEC controls the relevant preparation environment. The C-SEC is the secondary containment space. A CSTD works at connections along the transfer pathway. Each addresses a different part of the exposure problem. A connector system cannot justify open-bench HD compounding that otherwise requires a C-PEC.

Common components include a vial adaptor, a syringe component and a bag or administration-set connector. The components used depend on the particular system and the intended procedure. Use a manufacturer-validated configuration; apparent physical fit between two connectors does not establish compatible closed-system performance.

A closed connection also does not remove the need for appropriate aseptic technique or PPE. Follow the relevant instructions for disinfection, connection, disconnection and disposal. These are task-specific practices that must be taught with the actual equipment, rather than inferred from a generic picture of a CSTD.

Product names and mechanisms

Manufacturer resources identify systems such as PhaSeal Optima, EQUASHIELD, ChemoClave, Tevadaptor and OnGuard 2 . For example, ICU Medical's ChemoClave brochure identifies a CSTD, while a biological safety cabinet is a C-PEC and a wipe-sampling kit measures contamination.

Product generations matter. BD's US product page states that the original PhaSeal system was discontinued in 2026 , with last orders on 1 July and final support on 1 October; that notice expressly excludes PhaSeal Optima . An older brand list is therefore not a reliable current purchasing or compatibility list.

USP's FAQ discusses both barrier and air-cleaning/filtration CSTD technologies. Do not assume that every product bearing a familiar name uses the same mechanism across all generations, or that a generic filter description proves containment for a specific drug. Consult the exact system's current instructions and compatibility information. Product marketing does not replace the applicable standard or an evaluation of the complete configuration.

Compatibility applies to the exact formulation and pathway

Physical and chemical compatibility must be checked for the specific drug formulation and device , not merely the active ingredient's name. A solvent can affect device materials, and two formulations containing the same drug may have different restrictions. The dosage form and intended route must also support the proposed transfer configuration.

FDA's 2015 warning about Treanda injection solution illustrates the formulation boundary: its incompatibility warning concerns contact with devices containing polycarbonate or acrylonitrile-butadiene-styrene (ABS) before dilution , and distinguishes that solution from the lyophilised formulation. Do not generalise that historical warning into “all bendamustine formulations are incompatible with all CSTDs.” Check the current labelling for the product actually used and the device manufacturer's instructions.

Avoid universal route lists such as “no product can ever be used for any irrigation or intrathecal preparation.” A device intended for one pathway is not automatically suitable for another; a proposed configuration requires explicit supporting instructions. If the available device is incompatible, do not force its use or abandon the other required controls. Escalate through the designated person and the appropriate clinical and manufacturer channels to establish a suitable approach.

Work through a scenario in the right order

First identify whether the question describes receiving, compounding, dispensing or administration. Then identify the drug's applicable classification, the dosage form and whether the specified device is compatible. Only after those conditions are established should you choose the required-versus-recommended statement.

For example, a pharmacy has a device that is unsuitable for a particular formulation. The safe response is to resolve compatibility and the approved handling approach before proceeding. “CSTDs are protective” is not a reason to use a known incompatible device, and the incompatibility is not a reason to omit a C-PEC or PPE where those controls are required.

This sequence keeps the two common errors separate: extending a conditional administration requirement to every HD activity, and using a recommendation for compounding as an excuse to ignore the other mandatory containment measures.